OwnershipAccovion GmbH was spun off from Aventis Pharma Deutschland GmbH on January 1st, 2002. Accovion is incorporated in Eschborn (Frankfurt), Germany. Shareholders are:
HeidelbergCapitalHeidelbergCapital is an independent Private Equity Funds Group, specialising in Secondary Direct Investments, e.g. the acquisition of shareholdings in companies previously held by private equity/venture capital funds or banks. HeidelbergCapital was founded mid 2007 by Prof. Dr. Martin Weiblen, former Managing Director of a multi-billion family office in London/U.K. and advisor to several Life Science-Funds. The company is jointly managed with Dr. Clemens Doppler, former Partner at 3i, the British Private Equity Group. The New York based Private Equity Investor Auda has committed c150m USD for the first fund, HeidelbergCapital Private Equity Fund I. The portfolio of HeidelbergCapital ranges from investments in later stage venture companies with a proven business model to established mid-size operations. As an active partner, HeidelbergCapital supports the companies in strategic business decisions, but also provides, where appropriate, funding for further growth. About HeidelbergCapital: www.heidelbergcapital.de Creathor VentureCreathor is one of Germany's leading early-stage venture capital firms with a focus on investments in innovative technologies and business concepts in the sectors life science, communications, IT, optics, micro- and nano technologies. Creathor's team, with its general partner and founder of former Technologieholding VC GmbH, Dr. Gert Köhler and partners Ingo Franz and Karlheinz Schmelig, has a successful track record of more than 20 years of investing in high-tech companies. About Creathor Venture: www.creathor.de |